News

Merck announces next steps on Zilmax

Merck Animal Health says it has made significant progress in its plan to bring its beta agonist Zilmax back on the market.

Merck suspended sales of the growth-promoting feed additive last year when concerns emerged that it might cause lameness in cattle.

On Wednesday, the company provided an update to its five-step plan to revive the product.  The plan includes a certification program for users of Zilmax, label modifications and closely-monitored field trials.

Merck says the FDA has approved an updated label to include “component feeding”, an alternative method of administering Zilmax using a targeted lower dose.  The company notes that a comprehensive review of the product shows it is safe when used according to its product label and in conjunction with sound animal husbandry practices.

Merck did not provide a timeline on when Zilmax may be reintroduced.